Antiagiogenesis of Ginsenoside Rg3 in Severe Combined Immunodeficient Mice with
Human Overian Carcinoma
[Abstract] Objective
To investigate the antiangiogenesis of ginsenoside Rg3 in severe
combined immunodeficient (SCID) mice with human ovarian carcinoma by detecting
vascular endothelial growth factor (VEGF), mRNA, VEGF protein level and
microvascular density (MVD)
Methods
The SCID mice with human ovarian carcinoma SKOV3 cells were treated with Rg3
(300µg 400??), mice with phosphate buffered solution (PBS) and without Rg3 and
PBS were used as control . Tumor volume, metastasis, ascites, VEGF mRNA, VEGF
protein and MVD were detected. The level of VEGF mRNA in tumor tissue was
determined by relative quantative reverse transcription polymerase chain
reaction. VEGF protein level in sera and ascitic fluids were determined by
enzyme-linked immunosorbent assay. MVD was calculated by immunohistochemistry
(antiCD34).
Results
1 No ascites was formed and the size of metastasis decreased in
SKOV3/ Rg3 group.
2 Expression of VEGF mRNA level in SKOV3/ Rg3 group (119?16) was lower
significantly than those of the control groups (254 ?4, 273 ?44, respectively,
p<0.05).
3 Serum VEGF level in SKOV3/ Rg3 group [(14.6?.7)pg/ml was lower
significantly than those of SKOV3 group and SKOV3/PBS group [(18.5?.1)and (20.5
?.7) pg/ml, respectively, p<0.05J.
4 MVD in tumor tissues of SKOV3/ Rg3 group (43 ?) was lower than that of
each control group (65 ?12, 73 ?10, respectively, p<0.05).
Conclusion
Ginsenoside Rg3 can block angiogenesis and inhibit tumor growth and metastasis
by downregulating the expression of VEGF mRNA and protein and reducing
microvascular density.
[Key words] Ovarian neoplasms; Mice SCID; Neovascularization, pathologic;
Ginsenoside
